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BACKGROUND: Elderly patients have a higher burden of comorbidities that influence clinical outcomes. We aimed to compare 
in- hospital outcomes in patients ≥80 years old to younger patients, and to determine the factors associated with increased 
risk of major adverse events (MAE) after left atrial appendage closure.
METHODS AND RESULTS: The National Inpatient Sample was used to identify discharges after left atrial appendage closure 
between October 2015 and December 2018. The primary outcome was in- hospital MAE defined as the composite of post-
procedural bleeding, vascular and cardiac complications, acute kidney injury, stroke, and death. A total of 6779 hospitaliza-
tions were identified, of which, 2371 (35%) were ≥80 years old and 4408 (65%) were <80 years old. Patients ≥80 years old 
experienced a higher rate of MAE compared with those aged <80 years old (6.0% versus 4.6%, P=0.01), and this difference 
was driven by a numerically higher rate of cardiac complications (2.4% versus 1.8%, P=0.09) and death (0.3% versus 0.1%, 
P=0.05) among individuals ≥80 years old. In patients ≥80 years old, higher odds of in- hospital MAE were observed in women 
(1.61- fold), and those with preprocedural congestive heart failure (≈2- fold), diabetes (≈1.5- fold), renal disease (≈2.6- fold), ane-
mia (≈2.7- fold), and dementia (≈5- fold). In patients <80 years old, a higher risk of in- hospital MAE was encountered among 
women (≈1.4- fold) and those with diabetes (≈1.3- fold), renal disease (≈2.6- fold), anemia (≈2- fold), and dyslipidemia (≈1.2- fold).
CONCLUSIONS: Patients ≥80 years old had higher rates of in- hospital MAE compared with patients aged <80 years old. Female 
sex and the presence of heart failure, diabetes, renal disease, and anemia were factors associated with in- hospital MAE 
among both groups.
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The prevalence of atrial fibrillation increases with age,1 as does the risk of cerebrovascular acci-dents.2– 5 Moreover, its has been shown that in-
dividuals aged 80 years or older have >20% of atrial 
fibrillation– related strokes5 and these are often more 
severe in terms of disability and mortality.5– 7 While 
oral anticoagulation therapy is the mainstay for throm-
boembolic cerebrovascular accidents prevention,6,8 
elderly patients are at increased risk of bleeding 
events3,9; hence, these drugs are often underused, 
mainly because of advanced age or the perceived 
high- risk of bleeding complications, falls, or even 
polypharmacy.3,6,7,10
Studies have demonstrated the safety and efficacy 
of left atrial appendage closure (LAAC) to reduce the 
risk of stroke in patients with atrial fibrillation,11– 13 and 
current guidelines recommend LAAC for individuals 
in whom long- term oral anticoagulation is considered 
either suboptimal or contraindicated.6,8 Patients re-
ferred for LAAC often present with overlapping risks 
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of systemic thromboembolism and bleeding events. 
In addition, elderly patients are generally frailer and 
have higher comorbidity burden, both of which often 
co- exist and influence clinical outcomes.14,15 Therefore, 
we aimed to compare in- hospital outcomes in patients 
≥80 years old to younger patients, and to determine 




We conducted a cohort- based observational study 
using the National Inpatient Sample (NIS) database, 
a nationally representative and all- payer publicly avail-
able database of hospitalized patients in the United 
States. The NIS database was developed by the 
Agency for Healthcare Research and Quality as a part 
of the Healthcare Cost and Utilization Project, which 
includes hospital information for >7 million hospital dis-
charges annually and ≈20% stratified weighted sample 
of all discharges from United States community hospi-
tals.16 The authors declare that all supporting data are 
available within the article and its online supplementary 
files. Institutional review board and ethics committee 
approval was obtained from The Western University 
Health Science Research Ethics Board, and patient 
consent was not required because of the nature of this 
study.
Study Population
Between October 2015 and December 2018, hospitali-
zations for LACC, as a primary procedure, were identi-
fied using the International Classification of Diseases, 
Tenth Revision, Clinical Modification (ICD- 10- CM) pro-
cedure code 02L73DK (occlusion of left atrial append-
age with intraluminal device, percutaneous approach). 
For this study, individuals were divided into 2 groups, 
those ≥80 years old and those <80 years old, and ICD- 
10- CM codes were used to identify patient’s base-
line characteristics through the Charlson comorbidity 
index17 (CCI, Table S1), and the Elixhauser comorbid-
ity score18 (ECS, Table S2). The CHA2DS2- VASc score 
was used to estimate the thromboembolic risk.
Outcome Measures
The primary outcome of interest was the occurrence 
of in- hospital major adverse events (MAE). In- hospital 
MAE were identified using ICD- 10- CM codes and de-
tailed in Table  S3, and this included a composite of 
postprocedural bleeding, cardiac and vascular com-
plications, acute kidney injury, stroke, or transient is-
chemic attack and death.
Statistical Analysis
Categorical variables are expressed as counts and 
percentages and continuous variables are presented 
as mean±SD or median (interquartile range [IQR]) ac-
cording to variable distribution. Because of Healthcare 
Cost and Utilization Project data use agreement, vari-
ables in tables with <10 discharge records are dis-
played as “<10”. Differences between patients ≥80 and 
<80 years old were evaluated using 2- sided Student t 
test or Wilcoxon rank- sum test for continuous variables 
and the χ2 test for categorical variables, accordingly, 
adjusting for a survey sampling design. P values for 
each variable were computed adjusting for sampling 
discharge- level weights, cluster, and strata provided by 
NIS and as recommended by Agency for Healthcare 
Research and Quality during survey- specific analysis.
The Cochran- Armitage trend test was used for 
detecting linear trends for complications over the 
time. Length of stay was calculated by subtracting 
the admission date from the discharge date. Hospital 
CLINICAL PERSPECTIVE
What Is New?
• This study represents a comprehensive ap-
praisal on age- related differences and 
in- hospital outcomes following left atrial ap-
pendage closure.
• Patients ≥80  years old had higher rates of in- 
hospital complications compared with patients 
<80 years old.
• Burden of comorbidities was associated with 
in- hospital adverse events following left atrial 
appendage closure in patients ≥80  years old 
and those aged <80 years old.
What Are the Clinical Implications?
• These findings have significant implications 
for the understanding of how age- related out-
comes may differ in patients undergoing left 
atrial appendage closure.
Nonstandard Abbreviations and Acronyms
CHA2DS2- VASc Congestive heart failure, 
Hypertension, Age ≥75  years, 
Diabetes mellitus, prior stroke 
or transient ischemic attack, 
age 65 to 74  years, vascular 
disease (including previous 
myocardial infarction), and 
female sex
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volumes were determined based on the annual num-
ber of LAAC performed by each hospital in a given 
year.
Factors associated with the primary outcome for 
patients ≥80 and <80 years old were assessed sep-
arately. We first conducted the univariate analysis for 
each outcome with a single variable; then, the vari-
ables associated with outcome variable from univariate 
analysis with a P value of <0.10 were included in mul-
tivariable models along with comorbidities. In addition, 
clinically relevant variables, chosen a priori, such as 
age, sex, and race were also included in multivariable 
models.
To account for the 2- level hierarchical structure of 
the NIS database (patients are nested within hospitals), 
multilevel modeling was applied, allowing the inter-
cepts to vary across hospitals for in- hospital MAE with 
adjustment of the sampling weight. To assess the ef-
fect of age ≥80 years old in the whole cohort, the multi-
level logistic regression model was fitted first adjusting 
for, in addition to sex, race and relevant comorbidities, 
then separately for patients ≥80 and <80 years old.
Area under the receiver operating characteris-
tic curve analysis was conducted for each model to 
assess its discrimination ability for in- hospital MAE. 
The goodness- of- fit of the model was assessed using 
Akaike information criterion and comparatively, a lower 
Akaike information criterion indicates that a model fits 
the data better. The model’s calibration was evalu-
ated by the Brier score that was calculated from mean 
squared error of prediction for each model. Differences 
were considered statistically significant at P values of 
<0.05. Statistical analyses were performed using R 




A total of 6779 hospitalizations were identified in the 
NIS dataset as having undergone LAAC as a primary 
procedure between October 1, 2015 and December 31, 
2018. Of these, 2371 (35%) were ≥80 years old (mean 
age 84.1±3.0 years old) and 4408 (65%) were <80 years 
old (mean age 71.6±6.3 years old). Interestingly, while 
the CCI was lower in patients ≥80 years old compared 
with <80  years old (1.9±1.7 versus 2.1±1.7, P<0.001), 
Figure 1. Proportion of components in Charlson Comorbidity Index.
Because of the very low proportions, mild liver disease and moderate– severe liver disease were pooled, leading to 16 variables 
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the ECS was higher in those ≥80 years old compared 
with <80 years old (9.9±5.7 versus 9.6±5.9, P=0.03). 
The group- based distribution of CCI and ECS are 
presented in Figures  1 and 2, respectively. Patients 
≥80 years old showed a higher CHA2DS2- VASc score 
(4.7±1.4 versus 4.0±1.5, P<0.001) and 100% of them 
presented with a high thromboembolic risk (CHA2DS2- 
VASc score ≥2, Figure 3) while 97% in the <80 years 
old cohort did (Table 1). Remaining baseline character-
istics are presented in Table 1.
In- Hospital Complications
The composite of in- hospital MAE occurred in 5.1% of 
patients, with statistical difference between patients 
≥80 and <80  years old (6.0% versus 4.6%, P=0.01); 
and this difference was mainly driven by the numeri-
cally higher rate of cardiac complications (2.4% versus 
1.8%, P=0.09) and death (0.3% versus 0.1%, P=0.05) 
among individuals ≥80  years old as compared with 
<80 years old (Table 1).
A quarterly analysis indicates that the number of 
LAAC procedures increased over time. Based on the 
Cochran- Armitage trend test, while the incidence of 
in- hospital MAE significantly decreased from 16.7% 
in October to December 2015 to 7.6% in October to 
December 2018 in patients ≥80 years old (Ptrend=0.02), 
it remained steady (6.0%– 6.5%, Ptrend=1.00) among 
those <80 years old (Figure 4).
To further evaluate the factors associated with 
in- hospital MAE, the patient’s baseline, and peripro-
cedural characteristics according to age ≥80 and 
<80 years old are detailed in Table 2. Patients in the 
≥80- year- old group who experienced in- hospital MAE 
had more previous history of diabetes (39% versus 27%, 
P=0.003), congestive heart failure (51% versus 37%, 
P=0.003), renal disease (42% versus 23%, P<0.001), 
dementia (9.2% versus 4.5%, P=0.01), depression 
Figure 2. Proportion of components in Elixhauser Comorbidity Score.
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(13% versus 5.7%, P<0.001), and anemia (35% ver-
sus 16%, P<0.001). Patients in the <80- year- old group 
who experienced in- hospital MAE had more previous 
history of dyslipidemia (67% versus 60%, P=0.03), di-
abetes (47% versus 38%, P=0.01), congestive heart 
failure (49% versus 38%, P=0.001), renal disease (42% 
versus 21%, P<0.001), and anemia (33% versus 16%, 
P<0.001). In both cohorts, the proportion of patients 
with in- hospital MAE increased with the increase in 
comorbidity burden as assessed by the CCI (2.7±1.8 
versus 1.8±1.9, in patients ≥80 years old and 2.7±2.0 
versus 2.1±1.7 in those <80  years old, P<0.001 for 
both), and ECS (11.6±6.2 versus 9.9±5.6, P=0.001, in 
patients ≥80 years old, and 11.93±6.6 versus 9.5±5.9, 
P<0.001, in those <80 years old), Table 2.
Length of Hospital Stay and Cost
The overall median length of stay was similar for 
patients ≥80 and <80  years (P=0.38), Table  1. The 
length of stay was significantly longer among those 
≥80 years old and <80  years old who experienced 
in- hospital MAE compared with counterparts who 
did not experience in- hospital MAE (Wilcoxon rank- 
sum test, P<0.001, for both). Patients ≥80 years old 
and <80 years old who experienced in- hospital MAE 
had a significantly higher index cost compared with 
those who did not have complications ($28 727; IQR, 
$21 145– 37 480 USD versus $24 054; IQR, $18 803– 
29 338 USD and $30 934; IQR, $23 706– 38 334 USD 
versus $24 240; IQR, $18 357– 29 974 USD, respec-
tively) (Table 2).
Associations With In- Hospital 
Complications
After multilevel modeling adjusting for age, sex, race, 
and relevant comorbidities, the risk of in- hospital MAE 
for the whole cohort was significantly increased by fac-
toring age ≥80  years old (1.4- fold) as well as female 
sex (1.3- fold). The presence of congestive heart failure 
(odds ratio [OR], 1.32 [95% CI, 1.16– 1.49]), diabetes 
(OR, 1.28 [95% CI, 1.13– 1.45]), renal disease (OR, 2.38 
[95% CI, 2.08– 2.72]), weight loss (OR, 3.39 [95% CI, 
1.79– 6.43]), dementia (OR, 2.29, [95% CI, 1.72– 3.04]), 
anemia (OR, 2.27, [95% CI, 1.98– 2.60]), and dyslipi-
demia (OR, 1.16 [95% CI, 1.02– 1.32]) had higher im-
pact on the risk of MAE (Figure 5A). Among patients 
≥80  years old, higher odds of in- hospital MAE were 
observed in women (1.61- fold), and individuals with 
Figure 3. Proportion of components in CHA2DS2- VASc score.
CHA2DS2- VASc indicates Congestive heart failure, Hypertension, Age ≥75 years, Diabetes, prior Stroke or 
transient ischemic attack, Vascular disease (including previous myocardial infarction), Age 65 to 74 years, 
Sex category; and TIA, transient ischemic attack.D
ow
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Table 1. Baseline Characteristics and In- Hospital Outcomes of the Study Population
Patient characteristics All (n=6779) ≥80 y (n=2371) <80 y (n=4408) Adjusted P value*
Mean age, y 76.0±8.0 84.1±3.0 71.6±6.3 <0.001
Women 2830 (42) 1041 (43.9) 1789 (40.6) 0.01
Race‡
White 5663 (86) 2037 (89) 3626 (85) <0.001
Non- White† 908 (14) 264 (11) 644 (15)
Type of admission§
Elective 6175 (91) 205 (91) 379 (91) 0.95
Nonelective 584 (9) 2159 (9) 4016 (9)
Median household income‖
0– 25th percentile 1353 (20) 423 (18) 930 (21) 0.01
26– 50th percentile 1740 (26) 605 (26) 1135 (26)
51– 75th percentile 1864 (28) 672 (29) 1192 (27)
76– 100th percentile 1725 (26) 638 (27) 1087 (25)
Patient location¶
Urban 5688 (84) 2044 (86) 3644 (83) <0.001
Rural 1082 (16) 324 (14) 758 (17)
Hospital teaching status and location
Rural 124 (1.8) 43 (1.8) 81 (1.8)
Urban nonteaching 630 (9.3) 228 (9.6) 402 (9.1) 0.80
Urban teaching 6025 (89) 2100 (89) 3925 (89)
Hospital bed- size
Small 727 (11) 288 (12) 439 (10)
Medium 1423 (21) 499 (21) 924 (21) 0.02
Large 4629 (68) 1584 (67) 3045 (69)
Primary payer
Medicare 6011 (89) 2246 (95) 3765 (86) <0.001
Medicaid 81 (1.2) <10 (0.3) 73 (1.7)
Private insurance 547 (8.1) 78 (3.3) 469 (11)
Other 126 (1.9) 34 (1.4) 92 (2.1)
Comorbidities
Smoking 2358 (35) 787 (33) 1571 (36) 0.04
Dyslipidemia 4058 (60) 1414 (60) 2644 (60) 0.78
Hypertension 5822 (86) 2025 (85) 3797 (86) 0.41
Diabetes 2357 (35) 660 (28) 1697 (38) <0.001
Previous myocardial infarction 852 (13) 270 (11) 582 (13) 0.03
Previous CABG 1012 (15) 400 (17) 612 (14) 0.001
Congestive heart failure 2604 (38) 917 (39) 1677 (38) 0.39
Valvular disease 1441 (21) 638 (27) 803 (18) <0.001
Previous cerebrovascular disease 1951 (29) 685 (29) 1266 (29) 0.88
Peripheral vascular disease 703 (10) 260 (11) 443 (10) 0.24
Renal disease 1553 (23) 574 (24) 979 (22) 0.06
Chronic pulmonary disease 1481 (22) 451 (19) 1030 (23) <0.001
Obesity 1129 (17) 235 (9.9) 894 (20) <0.001
Dementia 187 (2.8) 113 (4.8) 74 (1.7) <0.001
Rheumatic disease 199 (2.9) 60 (2.5) 139 (3.2) 0.15
Liver disease 87 (2.6) 14 (1.3) 73 (3.3) 0.001
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congestive heart failure (≈2- fold), diabetes (≈1.5- fold), 
renal disease (2.6- fold), anemia (≈2.7- fold), and demen-
tia (≈5- fold), Figure 5B. In patients <80  years, higher 
risk of in- hospital MAEs were encountered among 
women (≈1.4- fold) as well as patients with diabetes 
(≈1.3- fold), renal disease (≈2.6- fold), anemia (≈2- fold), 
and dyslipidemia (1.2- fold) (Figure 5C).
In the whole cohort, the area under the receiver 
operating characteristic curves, Akaike informa-
tion criterion, and Brier score were 0.91 (95% CI, 
Patient characteristics All (n=6779) ≥80 y (n=2371) <80 y (n=4408) Adjusted P value*
Depression 510 (7.5) 147 (6.2) 363 (8.2) 0.002
Cancer 160 (2.4) 65 (2.7) 95 (2.2) 0.13
Anemia 1130 (17) 406 (17) 724 (16) 0.46
Charlson Comorbidity Index 2.1±1.7 1.9±1.7 2.1±1.7 <0.001
0 1183 (18) 458 (19) 725 (16) 0.001
1 1857 (27) 672 (28) 1185 (27)
2 1477 (22) 509 (22) 968 (22)
≥3 2262 (33) 732 (31) 1530 (35)
Elixhauser Comorbidity Score 9.8±5.9 9.9±5.7 9.6±5.9 0.03
≤0 84 (1.2) 21 (0.9) 63 (1.4) 0.05
1– 5 2401 (36) 814 (4) 1587 (36)
6– 10 1418 (21) 489 (21) 929 (21)
≥11 2876 (42) 1047 (44) 1829 (42)
CHADS2 score 2.8±1.3 3.1±1.2 2.6±1.3 <0.001
≥2 5726 (84) 2212 (93) 3514 (80) <0.001
CHA2DS2- VASc score 4.3±1.5 4.7±1.4 4.0±1.5 <0.001
≥2 6629 (98) 2371 (100) 4258 (97) <0.001
Year of procedure
2015 (October– December) 114 (1.7) 30 (1.3) 84 (2.0) 0.01
2016 (January– December) 1017 (15) 340 (14) 677 (15)
2017 (January– December) 2163 (32) 719 (30) 1444 (33)
2018 (January– December) 3485 (51) 1282 (54) 2203 (50)
In- hospital MAE 345 (5.1) 142 (6.0) 203 (4.6) 0.01
Bleeding complications 38 (0.6) 15 (0.6) 23 (0.5) 0.55
Cardiac complications 139 (2.1) 58 (2.4) 81 (1.8) 0.09
Vascular complications 30 (0.4) 14 (0.6) 16 (0.4) 0.18
Stroke 24 (0.4) 12 (0.5) 12 (0.3) 0.12
Acute kidney injury 161 (2.4) 60 (2.5) 101 (2.3) 0.53
Death <10 (0.1) <10 (0.3) <10 (0.1) 0.05
Length of stay, d 1 (1– 1) 1 (1– 1) 1 (1– 1) 0.23
Length of stay (d, range) 0– 35 0– 35 0– 33 …
≤1 d 5811 (86) 2010 (85) 3801 (86) 0.10
>1 d 361 (14) 361 (15) 607 (14)
Index admission cost#, USD 24 343 (18 588– 30 166) 24 168 (18 886– 29 753) 24 469 (18 487– 30 381) 0.38
Values are expressed as mean±SD, median (interquartile range), or % unless otherwise noted. Exact counts (n) for variables with <10 patients are not 
detailed as per the Healthcare Cost and Utilization Project data use agreement. The rate of the overall incidence of cardiac tamponade (computed as cardiac 
complication) was 0.62% (0.76% among those ≥80  years old and 0.55% among those <80  years old). CABG indicates coronary artery bypass surgery; 
CHA2DS2- VASc, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack, Vascular disease (including 
previous myocardial infarction), Age 65 to 74 years, Sex category; MAE, major adverse event; and USD, United States dollar.
*Adjusted P values for each variable were computed from adjusting sampling design by discharge- level weights, cluster, and strata.
†Non- white race/ethnicity included Black, Hispanic, Asian/Pacific islander, Native Americans and “other” as per National Inpatient Sample (NIS) categorization.
‡Race was missing in 3.1%.
§Type of admission was missing in 0.3%.
‖Median household income was missing in 1.4%.
¶Urban location was defined as counties in metro areas of ≥50 000 population.
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0.89– 0.92), 10 473, and 0.057, respectively. In those 
≥80 years old, the area under the receiver operat-
ing characteristic curves, Akaike information crite-
rion, and Brier score were 0.95 (95% CI, 0.93– 0.96), 
3511, and 0.074, respectively; whereas these values 
were 0.94 (95% CI, 0.93– 0.95), 5666, and 0.053, 
respectively, in those ≥80 years old, (Figure 5).
DISCUSSION
In this cohort of 6779 hospitalizations for LAAC, close 
to 1 in 3 patients were ≥80 years old and, therefore, 
represents one of the largest cohorts of patients 
≥80  years of age who underwent LAAC. The overall 
cohort presented with high burden of comorbidities. 
Patients ≥80 years old experienced higher rates of in- 
hospital complications mainly driven by the numerically 
higher rate of cardiac complications and death among 
individuals ≥80 years old as compared with <80 years 
old. Women and the presence of heart failure, diabe-
tes, renal disease, and anemia were factors commonly 
associated with in- hospital adverse events among 
both groups.
Contribution to Previous Studies
Studies have shown that among individuals ≥80 years 
of age, >80% of this population present with multiple 
comorbid conditions, and comorbidity burden is a 
strong predictor of poor outcomes.14,15,19– 23 One po-
tential explanation for the differences in CCI and ECS 
(lower CCI in patients ≥80 years old while higher ECS 
as compared with <80  years old) would be the fact 
that the CCI captures about half the number of comor-
bidities than the ECS and, therefore, the differences in 
P values are likely driven by the difference in sample 
sizes.
Elderly patients are generally more fragile, and 
more prone to complications during interven-
tional procedures; therefore, the benefit of LAAC 
may indeed be limited or at least questioned. 
Nonetheless, as above- stated, elderly patients show 
a combined increased risk of thromboembolic and 
Figure 4. Temporal trends in left atrial appendage closure procedures performed quarterly and in- hospital complications 
from 2015 to 2018 according to age ≥80 years old and <80 years old.
Cochran- Armitage trend test shows statistically significant decrease in complication rates over time among ≥80 year- old patients. 







































































































































































































Age <80 years - Ptrend = 1.00
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bleeding events. Previous registry data showed 
similar periprocedural complications in patients <75 
versus ≥75 years old, although older patients had a 
higher incidence of cardiac tamponade.24 Another 
registry compared the safety and efficacy of LAAC 
in patients <85 versus ≥85  years old and revealed 
similar procedural success and no differences in 
procedure- related adverse events.25 Of note, the 
sample size of elderly patients included in these 2 
registries was indeed significantly smaller than ours 
(ie, 430 and 84 patients ≥75 and ≥85  years old, 
respectively).24,25
Our findings are relevant since elderly patients are 
often underrepresented in clinical trials and across 
a broad spectrum of health conditions, with marked 
disparities in the type of presentation, and clinical out-
comes.26,27 Moreover, our study presents national esti-
mates in which one third of the patients (n=2371) were 
≥80 years of age, and the overall number of patients 
who have undergone LAAC has increased over time, 
while the occurrence of in- hospital MAE appears to 
have improved.
Strengths and Limitations
The strength of our analysis lies in its large sample 
size, and that it is the first study to appraise the clinical 
impact of comorbidity burden in patients ≥80  years 
old undergoing LAAC. Nonetheless, this study pre-
sents with limitations. The main limitation lies in its 
retrospective nature and reliance on an administrative 
claims database, therefore, errors while coding may 
have occurred and thus affected the data gathering 
and the ability to adjust for unmeasured confound-
ers. Even though the event rates after LAAC were 
relatively low and hence pooled for a composite end 
point, postprocedural MAE are not well adjudicated 
in NIS. Moreover, pharmacologic agents such as an-
ticoagulation management were not available and 
remain a source for potential confounders in terms 
of bleeding or thromboembolic events. Finally, the im-
pact of these findings on long- term follow- up remains 
unknown.
CONCLUSIONS
In this cohort- based study including a large number 
of patients ≥80 years old who underwent LAAC, the 
rates of in- hospital MAE were higher compared with 
patients <80 years. Women and those with heart fail-
ure, diabetes, renal disease, and anemia experienced 
higher rates of in- hospital adverse events in both 
groups. Furthermore, adequately powered research 
is needed to develop a risk stratification model to help 
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Figure 5. Multilevel multivariable logistic regression analyses of factors associated with in- hospital MAE.
A, Whole cohort, (B) ≥80 years old, and (C) <80 years old. AIC indicates Akaike’s information criterion (lower values indicate better fit of 
the model); AUC, area under receiver operating characteristic curve; MAE, major adverse events; and OR, odds ratio. For continuous 
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Table S1. Charlson Comorbidity Index and ICD-10-CM codes. 
Comorbidity Points ICD 10-CM codes 
Myocardial infarction 1 I25.2 
Congestive heart failure 1 I09.81, I25.5, I42.0, I42.5 - I42.9, I43.x, I50.x 
Peripheral vascular disease 1 
I70.x, I71.x, I72.x, I73.1, I73.8, I73.9, I77.1, I77.7, I79.0, I79.1, I79.8, I79.2, K55.1, 
K55.8, K55.9, Z95.8, Z95.9 
Cerebrovascular disease 1 I69.x, Z86.73 
Dementia 1 F01.5, F02.8, F03.9, G30.x, G31.1, G31.8, G31.9 
Chronic pulmonary disease 1 I27.8, I27.9, J40.x - J47.x, J60.x - J67.x, J68.4, J70.1, J70.3, J84, J96.1 
Rheumatic disease 1 
L94.0, L94.1, L94.3, M05.x, M06.x, M08.x, M12.0, M12.3, M30.x, M31.0 - M31.3, 
M32.x - M35.x, M45.x, M46.5, M46.1, M46.8, M46.9, M48.8, M49.8 
Peptic ulcer disease 1 K25.5, K25.7, K25.9, K26.5, K26.7, K26.9, K27.5, K27.7, K27.9, K28.5, K28.7, K28.9 
Mild liver disease 1 
B18.x, K70.0 - K70.3, K70.9, K71.3 - K71.5, K71.7, K73.x, K74.x, K76.0, K76.0, K76.4, 
K76.8, K76.9, Z94.4 
Diabetes without chronic 
complication 
1 E08.9, E09.9, E10.9, E11.9, E13.9 
Diabetes with chronic complication 2 E08.2-E08.8, E09.x, E10.2 - E10.8, E11.2 - E11.8, E12.2 - E12.8, E13.2 - E13.8 
Hemiplegia 2 G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0 - G83.5, G83.8, G83.9, I69.x, R53.2 
Renal disease 2 I12.0, I13.1, N18.x, N19.x, N25.0, Z49.0 - Z49.2 
Cancer 2 
C00.x - C26.x, C30.x - C34.x, C37.x - C41.x, C43.x, C45.x - C58.x, C60.x - C76.x, C81.x 
- C85.x, C88.x, C90.x - C96.x
Moderate or severe liver disease 3 I85.0, I86.4, K72.1, K72.9, K76.5, K76.6, K76.7 
Metastatic solid tumor 6 C77.x - C80.x, R18.0 
AIDS 6 B20 








Table S2. Elixhauser Classification System and ICD-10-CM codes. 
 
Comorbidity Points ICD-10-CM codes 
Congestive heart failure 7 I09.81, I25.5, I42.0, I42.5 - I42.9, I43.x, I50.x 
Cardiac arrhythmias 5 
I44.1 - I44.3, I45.6, I45.9, I47.x - I49.x, R00.0, R00.1, 
R00.8, Z95.0 
Valvular disease -1 
A52.0, I05.x - I08.x, I09.1, I09.8, I34.x - I39.x, Q23.0 - 
Q23.3, Z95.2 - Z95.4 
Pulmonary circulation 
disorders 




I70.x, I71.x, I72.x, I73.1, I73.8, I73.9, I77.1, I77.7, 
I79.0, I79.1, I79.8, I79.2, K55.1, K55.8, K55.9, Z95.8, 
Z95.9 
Hypertension 0 I10.x, I11.x - I13.x, I15.x 
Paralysis 7 
G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0 - 




E75.0, E75.1, E75.2, E75.4, F84.2, G10.x - G13.x, 
G20.x - G21.x, G24.0, G24.2, G24.8, G25.4, G25.5, 
G30.0, G31.0, G31.1, G31.2, G31.8, G31.9, G32.8, 
G35.x - G37.x, G80.3 
Chronic pulmonary disease 3 
I27.8, I27.9, J40.x - J47.x, J60.x - J67.x, J68.4, J70.1, 
J70.3, J84, J96.1  
Diabetes, uncomplicated 0 E08.9, E09.9, E10.9, E11.9, E13.9 
Diabetes, complicated 0 
E08.2-E08.8, E09.x, E10.2 - E10.8, E11.2 - E11.8, 
E12.2 - E12.8, E13.2 - E13.8 
Hypothyroidism 0 E00.x - E03.x 
Renal failure 5 I12.0, I13.1, N18.x, N25.0, Z49.0, Z49.3, Z91.1, Z99.2 
Liver disease 11 
B18.x, I85.x, K70.x, K71.1, K71.3 - K71.5, K71.7, 
K72.x - K74.x, K75.4, K75.8, K76.0, K76.2 - K76.9, 
Z94.4 
Peptic ulcer disease, no 
bleeding 
0 
K25.5, K25.7, K25.9, K26.5, K26.7, K26.9, K27.5, 
K27.7, K27.9, K28.5, K28.7, K28.9 
AIDS/HIV 0 B20 
Lymphoma 9 
C81.x - C86.x, C88.x, C90.0, C90.2, C90.3, C96.x, 
D47.Z9 
Metastatic cancer 12 C77.x - C80.x, R18.0 
Solid tumor without 
metastasis 
4 
C00.x - C26.x, C30.x - C34.x, C37.x - C41.x, C43.x, 





L94.0, L94.1, L94.3, M05.x, M06.x, M08.x, M12.0, 
M12.3, M30.x, M31.0 - M31.3, M32.x - M35.x, M45.x, 
M46.5, M46.1, M46.8, M46.9, M48.8, M49.8 








Obesity -4 E66.x, Z68.3, Z68.4, Z68.5 
Weight loss 6 E40.x - E46.x, R63.4, R63.6 
Fluid and electrolytes 
disorders 
5 E22.2 
Blood loss anemia -2 D50.0 
Deficiency anemia -2 D501, D50.8, D50.9, D51.x - D53.x, D63.1, D63.8 
Alcohol misuse 0 
F10, E52, G62.1, I42.6, K29.2, K70.0, K70.3, K70.9, 
T51.x, Z71.4 
Drug abuse -7 F11.x - F16.x, F18.x, F19.x, Z71.5 
Psychosis 0 
F20.x, F22.x - F25.x, F28.x, F29.x, F30.1, F30.2, F31.2, 
F31.6, F44.8 
Depression -3 F20.4, F31.3 - F31.5, F32.x, F33.x, F34.1, F41.2, F43.2 
 
ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification. AIDS/HIV: 








Table S3. 10-CM codes for in-hospital major adverse events. 
Adverse Events ICD-10-CM codes 
Post procedural 
hemorrhage 
D7821, D7822, D7831, D7832, E89810, E89811, E89820, E89821, G9751, G9752, G9761, G9762, H59311, H59312, H59313, 
H59319, H59321, H59322, H59323, H59329, H59331, H59332, H59333, H59339, H59341, H59342, H59343, H59349, H9541, 
H9542, H9551, H9552, I97610, I97611, I97618, I9762, I97620, I97621, I97630, I97631, I97638, J95830, J95831, J95860, J95861, 
K91840, K91841, K91870, K91871, L7621, L7631, M96830, M96840, N99820, N99821, N99840, N9984 
Cardiac 
complications 
I2101, I2102, I2109, I2111, I2119, I2121, I2129, I213, I214, I219, I21A1, I21A9, I220, I221, I222, I228, I229, I469, I97710, I97790, 
I9788, I9789, I312, I314, I442, 0W9D30Z, 0W9D3ZX, 0W9D3ZZ, 0W9D40Z, 0W9D4ZX, 0W9D4ZZ, 02HK3JZ, 02HK3MZ, 
02HL3JZ, 02HL3MZ, 02H63JZ, 02H73JZ, 02HK3JZ, 02HL3JZ, 5A1213Z, 5A1223Z, 0JH60PZ, 0JH60PZ, 0JH63PZ, 0JH63PZ, 
0JH80PZ, 0JH80PZ, 0JH83PZ, 0JH83PZ, 0JH604Z, 0JH634Z, 0JH804Z, 0JH834Z, 0JH605Z, 0JH635Z, 0JH805Z, 0JH835Z, 
0JH606Z, 0JH636Z, 0JH806Z, 0JH836Z, T8111XA, 028D0ZZ, 02QD0ZZ, 02890ZZ, 02Q90ZZ, 02QF0ZZ, 02QG0ZZ, 02QH0ZZ, 
02QJ0ZZ, 02BK0ZZ, 02NK0ZZ, 02NL0ZZ, 02QF0ZZ, 02QA0ZZ, 02B50ZZ, 02RM0JZ, 02U50JZ, 02UM0JZ, 02U50JZ, 
02RM0JZ, 02UM0JZ, 02QF0ZZ, 02QG0ZZ, 02QH0ZZ, 02QJ0ZZ, 02U50JZ, 02UM0JZ, 02RM07Z, 02RM0KZ, 02U507Z, 
02U508Z, 02U50KZ, 02UM07Z, 02UM0KZ, 02U507Z, 02U508Z, 02U50KZ, 02RM07Z, 02RM0KZ, 02UM07Z ,02RK07Z, 
02RK0KZ, 02RL07Z, 02RL0KZ, 02U607Z, 02U608Z, 02U707Z, 02U708Z, 02U70KZ, 02UK0KZ, 02UL0KZ, 02Q50ZZ, 
02QM0ZZ, 02Q50ZZ, 02QM0ZZ, 02QB0ZZ, 02QC0ZZ, 02U50JZ, 021609P, 021609Q, 021609R, 02160AP, 02160AQ, 02160AR, 
02160JP, 02160JQ, 
02160JR, 02160KP, 02160KQ, 02160KR, 02160ZP, 02160ZQ, 02160ZR, 02W50JZ, 02WF07Z, 02WF08Z, 02WF0JZ, 02WF0KZ, 
02WG07Z, 02WG08Z, 02WG0JZ, 02WG0KZ, 02WH07Z, 02WH08Z, 02WH0JZ, 02WH0KZ, 02WJ07Z, 02WJ08Z, 02WJ0JZ, 
02WJ0KZ, 02WM0JZ, 02Q50ZZ, 02QM0ZZ, 021K0Z5, 021L0Z5, 02B60ZZ, 02B70ZZ, 02BK0ZZ, 02BL0ZZ, 02B60ZZ, 
02B70ZZ, 02BK0ZZ, 02BL0ZZ 
Post-procedural 
stroke or transient 
ischemic attack 
I6322, I63139, I63239, I63019, I63119, I63219, I6359, I6359, I6320, I6330, I6340, I6350, I6300, I63011, I63012, I63019, I6302, 
I63031, I63032, I63039, I6309, I6320, I63211, I63212, I63219, I63549, I6359, I638, I639, H3400, H3401, H3402, H3403, H3410, 
H3411, H3412, H3413, H34211, H34212, H34213, H34219, H34231, H34232, H34233, H34239, G450, G451, G458, G459, G9781, 




T1490, D7811, D7811, D7812, E3611, E3612, G9748, G9749, H59219, H59229, H9531, H9532, I9751, I9752, J957, J9572, K9171, 
K9172, L7611, L7612, M96820, M96821, N9971, N9972, T888XXA, S15009A, S15309A, S15209A, S158XXA, S090XX, 
S158XXA, S159XXA, S2500XA, S25109A, S2520XA, S25309A, S25409, S25409A, S25509A, S25809A, S2590XA, S3500XA, 
S3510XA, S35299A, S35219A, S35229A, S35239A, S35339A, S35349A, S35319A, S35329A, S358X9A, S35403A, S35406A, 
S35516A, S35513A, S35533A, S35536A, S3559XA, S358X9A, S3590XA, S45809A, S45009A, S45209A, S45109A, S55109A, 
S65109A, S55009A, S65009A, S65209A, S65309A, S65409A, S65509A, S45809A, S55809A, S65809A, S45909A, S55909A, 
S65909A, S75009A, S75109A, S75209A, S85309A, S85409A, S85009A, S85509A, S85109A, S85139A, S85809A, S85169A, 
S95109A, S75809A, S95809A, S75909A, S85909A, S95902A 
Acute kidney 
injury 
N170, N171, N172, N178, N179, N990, R34 
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